cell therapy financing

Capital is returning to regenerative medicine, but it is moving with far more discipline than the last financing cycle. Investors are still funding cell therapy, tissue engineering, and exosome platforms, yet capital now follows clinical proof, scalable manufacturing, and reimbursement visibility rather than platform promise alone. That shift is redefining how regenerative medicine companies raise, … Read more